New approach reduces immune response to tissue engineered vascular grafts

New approach reduces immune response to tissue engineered vascular grafts
Credit: Mary Ann Liebert, Inc., publishers

Using RNA interference (RNAi) technology to silence an immune-stimulating complex in endothelial cells (EC), the main cellular component of blood vessels, researchers have made it possible to use the plentiful supply of donor ECs instead of a patient's own cells to generate tissue engineered vascular grafts for transplantation. This innovative method, in which the treated EC retain their key features and functions, is reported in Tissue Engineering, Part A.

In the article entitled "Low Immunogenic Endothelial Cells Maintain Morphofunctional Properties Needed for Tissue Engineering," Skadi Lau, Dorothee Eicke, Constança Figueiredo, Ulrike Böer, and coauthors from Hannover Medical School, Germany describe their approach using lentiviral vector-mediated RNAi to silence the (HLA) class I complex in donor EC collected from three different sources: peripheral blood, umbilical cord blood, and vein. The researchers demonstrated that HLA I-silenced EC were still able to express essential surface biomarkers and compounds needed to form a tight barrier between cells, to produce factors important for blood coagulation and regulating blood vessel tone, and to form capillary-like tube structures when put into 3D fibrin gels.

"This article demonstrates the impact of RNA interference technology on the development of tissue engineered leveraging available allogeneic cell sources," says Tissue Engineering Co-Editor-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX.

Explore further

Vascular bypass grafting: A biomimetic engineering approach

More information: Skadi Lau et al, Low Immunogenic Endothelial Cells Maintain Morphological and Functional Properties Required for Vascular Tissue Engineering, Tissue Engineering Part A (2017). DOI: 10.1089/ten.tea.2016.0541
Citation: New approach reduces immune response to tissue engineered vascular grafts (2018, February 7) retrieved 12 December 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments